Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Jun 30.
Published in final edited form as: Brain Pathol. 2009 Jul 16;20(2):459–467. doi: 10.1111/j.1750-3639.2009.00322.x

Cerebral Microinfarcts Associated with Severe Cerebral β-Amyloid Angiopathy

Virawudh Soontornniyomkij 1,*, Matthew D Lynch 1, Sherin Mermash 1, Justine Pomakian 1, Haleh Badkoobehi 1, Ryan Clare 1, Harry V Vinters 1,2
PMCID: PMC3127860  NIHMSID: NIHMS140069  PMID: 19725828

Abstract

Cerebral amyloid angiopathy (CAA) is common in elderly individuals, especially those affected with Alzheimer's disease. To investigate whether the presence of severe CAA (SCAA) in the brains of demented patients was associated with a higher burden of old microinfarcts than those with mild CAA (MCAA), 18 brains with SCAA were compared to 21 brains with MCAA. Immunohistochemistry for CD68 was employed to highlight old microinfarcts in tissue blocks from various brain regions. Old microinfarcts, manually counted by light microscopy, were present in 14 of 18 SCAA brains, and in 7 of 21 MCAA brains (P = 0.01, 2-tailed Fisher’s exact test). The average number of old microinfarcts across geographic regions in each brain ranged from 0 to 1.95 (mean rank 24.94, sum of ranks 449) in the SCAA group, and from 0 to 0.35 (mean rank 15.76, sum of ranks 331) in the MCAA group (P = 0.008, 2-tailed Mann-Whitney U test). Frequent old microinfarcts in demented individuals with severe CAA may contribute a vascular component to the cognitive impairment in these patients.

Keywords: cerebrovascular disease, dementia, multi-infarct dementia, vascular dementia

INTRODUCTION

A significant proportion of dementing illnesses in the elderly are attributed to multiple pathologic processes that may confer their additive or synergistic effects to the development of cognitive decline (1, 5, 30, 32, 38, 39). Relatively common pathologic processes in this context include Alzheimer’s disease (AD), cerebrovascular disease, diffuse Lewy body disease, and remote hippocampal injury (16). Cerebrovascular disease may contribute clinically to cognitive impairment either as “pure” vascular dementia or a vascular component of mixed dementia, and may be associated pathologically with either multifocal/diffuse lesions or strategically placed focal lesions (5, 16, 34). The neuropathologic substrates of vascular dementia include cerebrovascular pathology, brain parenchymal injury resulting from it (e.g. hemorrhage, infarction, and subinfarctive injury), and other indirectly associated changes (e.g. Wallerian, retrograde, and trans-synaptic degeneration, manifest as white matter pallor and gliosis, and gray matter atrophy) (34). Both the type and burden of cerebrovascular pathology and brain parenchymal injury should be emphasized in neuropathologic evaluation for vascular dementia (16).

In a longitudinal clinicopathological study, lacunar infarcts and microinfarcts in many brain regions were a much more common substrate of ischemic vascular dementia than were large infarcts (34). In another similar study, cerebral microvascular disease, manifest as microinfarction and subcortical white matter damage, was found to correlate with dementia (7). In a semiquantitative assessment, old microinfarcts in either the neocortex or basal ganglia/thalamus were shown in the community-based Honolulu-Asia Aging Study (of 285 brains) to be independently associated with cognitive impairment (38). Among patients meeting neuropathologic criteria for AD, the coexistence of cerebral infarction has been shown to increase the likelihood of dementia in the Nun Study (31) and the severity of dementia in the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) study (15). In the Honolulu–Asia Aging Study, the effect of cerebral infarction on cognitive function was most apparent in patients with low densities of neocortical neuritic plaques (26).

In a significant proportion of brains with neuropathologically confirmed vascular dementia without concomitant AD, the presence of cerebral amyloid angiopathy (CAA) of severe degree correlated significantly with cortical microinfarcts (13, 14). In a retrospective case control study on brain biopsied specimens, CAA was shown to be a risk factor for cerebral infarction (4). It is possible that, in a subpopulation of AD patients, coexisting severe CAA leads to repetitive episodes of microinfarction or microhemorrhage, which may then contribute a vascular component to cognitive decline (33). Previous reports on the association between CAA and microinfarction in AD have shown somewhat conflicting results (6, 19, 2325), which might be related primarily to the differences in criteria used among laboratories to evaluate and grade the severity of CAA. In addition, none of these studies attempted to assess quantitatively the burden of cerebral microinfarcts.

The aim of our study was to elucidate the relationship between the presence of severe CAA and the burden of old microinfarcts in the brains of demented patients. Although foci of old microinfarction could be detected readily in most instances on hematoxylin and eosin (H&E) stained sections, to increase detection accuracy we employed CD68 immunohistochemistry to localize macrophages and microglia, markers of central nervous system injury. We hypothesized that the presence of severe CAA in the brains of demented patients was associated with a higher burden of old microinfarction than in those with mild CAA.

MATERIAL AND METHODS

Study sample

The brains of patients with a clinical diagnosis of dementia and a neuropathologic diagnosis of CAA were selected from the Alzheimer's Disease Research Center (ADRC) Brain Bank at the University of California, Los Angeles. Excluded from this study were cases that were recorded on the autopsy reports to have lacunar (>5 to ≤10 mm in greatest dimension) or large (>10 mm in greatest dimension) old infarcts, and cases with the number of tissue blocks available fewer than 12. A total of 39 cases selected from 2000 to 2007 were grouped on the basis of CAA severity into severe CAA (SCAA, 18 cases: S1 to S18) and mild CAA (MCAA, 21 cases: M1 to M21). The ADRC neuropathologic protocols used in evaluating autopsy cases have been described elsewhere (9). Specifically, all brains were examined according to the standardized autopsy dementia brain protocol, including 24 tissue blocks from various brain regions and 3 tissue blocks from the basal cerebral arteries for microscopic evaluation. In addition to H&E staining of the tissue blocks, four (from the right superior temporal, right occipital, left frontal, and left parietal regions) were subject to modified Bielshowsky staining and immunohistochemical studies for paired helical filament-tau (AT8, Piece Endogen), β-amyloid (Aβ) 1–40 (Chemicon), and Aβ1-42 (Chemicon); and two (from the anterior cingulate and left superior temporal regions) for alpha-synuclein (Chemicon) immunohistochemistry. The neuropathologic diagnosis of AD was made based upon CERAD (10) and Braak & Braak neurofibrillary tangle staging (3). The severity of CAA was assessed according to “Vonsattel criteria” (36, 37). The brains involved by Vonsattel grade III CAA mostly exhibited one or more features of CAA-associated microangiopathies such as microaneurysm formation or “double barrel lumen” formation (20). The brains with Vonsattel grade I CAA were classified into the MCAA group, and those with Vonsattel grade III CAA into the SCAA group.

Included in our present study for CD68 immunohistochemistry were formalin-fixed paraffin-embedded tissue blocks from the mid-frontal, dorsolateral posterior frontal, parietal, occipital, superior temporal, temporal pole, hippocampal, entorhinal, and anterior cingulate regions of both right and left cerebral hemispheres, and the cerebellum. All the tissue sections used were of regular size, fitting into 2.5×2.8 cm histology cassettes. The basal ganglia and thalamus were excluded, since these deep gray matter structures are usually spared of CAA but commonly involved by subcortical arteriosclerosis.

Immunohistochemistry for CD68

Six µm-thick tissue sections were deparaffinized and rehydrated through xylene and graded ethanol series and distilled water. The sections were incubated in 0.01 M sodium citrate buffer (pH 6) with microwave boiling (3 min ×3). After being washed with phosphate-buffered saline (PBS), the sections were treated for 10 min with 3% hydrogen peroxide in PBS, rinsed in PBS, and incubated for 30 min with 2.5% normal horse serum (ImmPRESS, Vector). Following overnight incubation in humidified chambers at 4°C with mouse monoclonal anti-human CD68 IgG1 primary antibody (clone KP1, Dako, 1:100 dilution in Dako antibody diluent), the sections were rinsed in PBS and then incubated in humidified chambers at 37°C for 60 min with HRP-labeled micropolymer conjugated horse anti-mouse IgG (H+L) reagent (ImmPRESS, Vector) in humidified box. Following PBS washing, the signals were developed with diaminobenzidine (DAB Substrate Kit for Peroxidase, Vector) for 1 min, and counterstained with hematoxylin (Biomeda) for 2 min. Brain tissue blocks showing old infarcts were used as positive tissue controls. For the negative control, the primary antibody was omitted. As built-in positive controls, CD68-immunoreactive perivascular and parenchymal microglia in the cerebral cortex (including those associated with senile plaques of AD) and in the white matter were highlighted in densities that varied from one block to another in each brain.

Light microscopic semiquantification

Old microinfarcts were defined as microscopic foci (≤5 mm in greatest dimension) of CD68-immunoreactive macrophage-infiltrated tissue destruction. Clusters of a few macrophages or perivascular macrophage infiltrates that were not accompanied by histologic evidence of tissue destruction were not counted as old microinfarcts in this study. By using a light microscope equipped with an eyepiece reticule (linear micrometer), old microinfarcts were screened on 10× and confirmed on 20× objective lens magnification independently by two neuropathologists (V.S. and H.V.V.), who were unaware of the CAA grade previously assigned on the autopsy reports. The discordance on identification of old microinfarcts was solved on double-headed microscopy. The number of old microinfarcts was recorded by manually counting by light microscopy on sections from each block. In each brain, the average number of old microinfarcts across geographic regions was calculated by dividing the total number of old microinfarcts by the number of blocks.

Statistical analysis

The Student’s t-test was used to compare continuous variables (i.e. age, fresh brain weight, and the number of tissue blocks examined) in the SCAA group to the MCAA group. The Mann-Whitney U test was employed to compare the number of old microinfarcts across brain regions of the SCAA group to that of the MCAA group. The Fisher’s exact test was used to determine associations between the two categorical proportions. Two-tailed P values of <0.05 were considered significant. All statistical analyses were performed on the SPSS version 13.0 for Windows software.

RESULTS

For each brain, the demographic data, fresh brain weight, dementing disease diagnosis, Braak & Braak stage, Vonsattel grade of CAA, number of tissue blocks examined, number of old microinfarcts, average number of old microinfarcts across brain regions, and existence and degree of subcortical arteriosclerosis and basal brain atherosclerosis are shown in Table 1. The postmortem delay and additional coexistent brain autopsy findings are shown in Table 2 and systemic diseases in Table 3, as online supplements. The patients at death ranged in age from 62 to 97 years (mean 82.3, SD 9.4) in the SCAA group (8 women and 10 men), and from 69 to 101 years (mean 84, SD 7.9) in the MCAA group (10 women and 11 men) (P = 0.54, two-tailed Student’s t-test of the mean ages). In the group with old microinfarcts (8 women and 13 men), the patients’ age ranged from 62 to 97 years (mean 84, SD 9.6), and in that without old microinfarcts (10 women and 8 men) from 72 to 101 years (mean 82.3, SD 7.2) (P = 0.54, two-tailed Student’s t-test of the mean ages). The brains ranged in fresh weight from 890 to 1,450 g (mean 1,152.9, SD 182.6, S8 brain weight not available) in the SCAA group, and from 860 to 1,360 g (mean 1,100.2, SD 138.9) in the MCAA group (P = 0.32, two-tailed Student’s t-test). The number of blocks available from each brain ranged from 14 to 19 (mean 16.4, SD 1.5) in the SCAA group, and from 13 to 19 (mean 16.7, SD 1.6) in the MCAA group (P = 0.66, two-tailed Student’s t-test). All of the 19 brain regions examined were present in the majority of brains, ranging from 28 to 39 brains (median 36), and showed old microinfarcts in at least 1 brain, among which the right and left parietal and occipital regions were most commonly involved (in 6, 8, 8, and 5 brains, respectively).

Table 1.

Summary of Demographic Data and Pertinent Neuropathologic Findings

Case Age-
Sex *
Brain
Weight
(g)
Dementing
Diseases
B & B
Stage
CAA
Grade
N
Blocks
N Microinfarct Aver N **
Microinfarct
Art-S
***
Ath-S
****

GM WM GM WM
S1 93-F 1030 Prob AD IV III 17 0 1 0 0.06 0 3
S2 91-M 1250 VD/Poss AD/B-HS IV–V III 14 2 0 0.14 0 1 2
S3 81-F 1030 Def AD V–VI III 16 0 0 0 0 0 2
S4 75-F 1000 Def AD VI III 14 1 0 0.07 0 1 1
S5 80-M 1450 Prob AD V–VI III 14 0 0 0 0 2 1
S6 83-M 1420 Def AD V III 18 1 0 0.06 0 0 2
S7 69-M 1110 Def AD VI III 17 1 3 0.06 0.18 0 1
S8 86-F NA Def AD VI III 15 0 0 0 0 3 1
S9 77-M 1240 Def AD IV III 16 9 10 0.56 0.63 3 2
S10 90-M 1110 Def AD V III 18 0 1 0 0.06 1 1
S11 80-M 1110 VD/Prob AD/B-HS IV III 16 4 0 0.25 0 3 2
S12 85-F 1170 Def AD VI III 16 2 0 0.13 0 2 1
S13 75-M 1110 VD/Def AD IV III 19 32 5 1.68 0.26 3 1
S14 87-M 1360 Def AD VI III 17 5 0 0.29 0 0 2
S15 74-F 950 Def AD VI III 18 0 0 0 0 3 3
S16 97-F 920 Def AD VI III 17 0 2 0 0.12 0 3
S17 62-M 1450 Prob AD III–IV III 18 0 1 0 0.06 0 1
S18 96-F 890 Def AD/L-HS VI III 16 4 2 0.25 0.13 3 3
M1 78-M 1360 Prob AD VI I 15 0 0 0 0 0 3
M2 74-M 1160 Def AD VI I 15 0 0 0 0 1 1
M3 76-M 1250 DLBD/Prob AD V–VI I 15 0 0 0 0 0 1
M4 89-M 940 Prob AD/L-HS VI I 13 1 0 0.08 0 1 3
M5 86-M 940 Def AD VI I 18 0 0 0 0 0 1
M6 90-M 1110 Def AD/R-HS VI I 18 0 3 0 0.17 0 2
M7 86-F 1130 Def AD V–VI I 17 0 0 0 0 2 2
M8 72-F 950 Def AD VI I 18 0 0 0 0 0 2
M9 86-F 1250 Def AD V I 18 0 1 0 0.06 1 1
M10 85-F 1050 Def AD VI I 17 0 0 0 0 0 1
M11 79-M 1320 Poss AD III–IV I 19 0 0 0 0 1 2
M12 87-M 1170 Def AD V I 17 2 4 0.12 0.24 3 1
M13 88-F 1070 Prob AD IV I 16 1 0 0.06 0 2 2
M14 81-M 1100 Def AD VI I 14 0 0 0 0 0 2
M15 69-F 910 Def AD VI I 18 0 4 0 0.22 1 1
M16 76-F 1070 Def AD VI I 18 0 0 0 0 1 1
M17 89-M 1165 Def AD VI I 18 0 0 0 0 2 2
M18 101-F 960 Def AD VI I 17 0 0 0 0 2 2
M19 95-M 1240 Prob AD V–VI I 16 2 0 0.13 0 3 1
M20 88-F 1100 Def AD VI I 15 0 0 0 0 1 3
M21 89-F 860 Def AD VI I 18 0 0 0 0 1 1

Abbreviations: S1–S18 = brains of demented patients with severe cerebral amyloid angiopathy; M1–M21 = brains of demented patients with mild cerebral amyloid angiopathy; F = female; M = male; NA = not available; AD = Alzheimer’s disease classified according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) into definite (= def), probable (= prob), and possible (= poss); VD = vascular dementia; HS = hippocampal sclerosis (B = bilateral, L = left, R = right); DLBD = diffuse Lewy body disease; B & B = Braak & Braak neurofibrillary tangle stage; CAA = severity of cerebral amyloid angiopathy graded in accordance with the Vonsattel criteria; N = number of; GM = gray matter; WM = white matter; Art-S = subcortical arteriosclerosis; Ath-S = basal brain atherosclerosis.

*

Age in years.

**

The average number of old microinfarcts across brain regions.

***

Degree of subcortical arteriosclerosis: 0 = absent, 1 = mild, 2 = moderate, 3 = severe.

****

Degree of basal brain atherosclerosis: 1 = mild, 2 = moderate, 3 = severe.

Table 2.

Additional Coexistent Brain Autopsy Findings

Case PMD Additional Coexistent Brain Autopsy Findings
S1 3 d Purkinje cell loss in superior cerebellar vermis
S2 NA WM pallor
S3 NA Early Parkinson's disease changes
S4 7 h None
S5 2 d Acute microhemorrhage in R parietal and L temporal cortex
S6 5 h Periventricular WM rarefaction; Focal Purkinje cell loss
S7 2 d Neuronal loss in substantia nigra and locus ceruleus (clinical parkinsonism)
S8 12 h Old microinfarct in thalamus; Periventricular WM rarefaction
S9 2 d WM rarefaction; Calcific vasculopathy
S10 3 d Neuronal loss in L prosubiculum
S11 1 d Subcortical WM rarefaction/gliosis; Neuronal loss in substantia nigra; Calcific vasculopathy
S12 4 d None
S13 1 d Old microinfarct in basal ganglia
S14 3 d Parkinson's disease
S15 14 h WM pallor/astrocytosis; Acute/subacute large WM infarct in L parietal and R/L occipital lobes
S16 12 h WM pallor; Old microhemorrhage in R amygdala
S17 NA None
S18 4 h Old microinfarct in L basal ganglia; Cavernous angioma at midbrain-pons junction
M1 4 h Focal Purkinje cell loss
M2 8 h R hippocampal glial scar
M3 6 h None
M4 2 d None
M5 12 h None
M6 1 d None
M7 5 d Periventricular WM rarefaction/gliosis; Focal Purkinje cell loss; Meningioma at falx cerebri
M8 1 d WM rarefaction/perivascular gliosis
M9 2 d Metastatic small-cell lung carcinoma in R occipital pole
M10 1 d None
M11 2 d Multifocal astrogliosis in R/L hippocampal formations, R basal ganglia, R temporal pole, and R cingulate gyrus
M12 1 d Rare Lewy bodies in locus ceruleus
M13 5 d Rare Lewy bodies in locus ceruleus
M14 22 h WM pallor/gliosis; Neuronal loss in locus ceruleus
M15 15 h WM pallor/astrocytosis; Neuronal loss in locus ceruleus
M16 21 h WM pallor
M17 15 h Multifocal microglial proliferation in R/L cerebral WM; Acute microinfarct in cerebellar GM
M18 1 d Focal Purkinje cell loss
M19 22 h Old hemorrhagic microinfarct in midbrain
M20 3 d WM pallor; Fourth ventricular subependymoma; R vestibular schwannoma
M21 4 h Calcific vasculopathy in basal ganglia

Abbreviations: S1–S18 = brains of demented patients with severe cerebral amyloid angiopathy; M1–M21 = brains of demented patients with mild cerebral amyloid angiopathy; PMD = postmortem delay; d = days; h = hours; NA = not available; R = right; L = left; WM = white matter; GM = gray matter.

Table 3.

Systemic diseases

Case Systemic Diseases
S1 HT; Athero-S; Pneumonia; Pseudomembranous colitis
S2 NA
S3 HT; Athero-S; Old MI; Cecal adenocarcinoma/liver metastasis
S4 None by history
S5 Low-grade pancreatic intraductal mucinous tumor; Pneumonia; Pulmonary embolism
S6 NA
S7 Athero-S; Old MI; Pulmonary embolism
S8 NA
S9 NA
S10 Athero-S; Pulmonary emphysema
S11 HT
S12 Athero-S; Nodular goiter; Pneumonia
S13 HT; Myxomatous degeneration of mitral and tricuspid valves; Pneumonia
S14 Athero-S; Acute/old MI; Marantic aortic endocarditis; Pneumonia
S15 HT
S16 None by history
S17 Alcohol abuse
S18 Clinical history of MI, Hypothyroidism, and Breast cancer lumpectomy
M1 NA
M2 Athero-S; Pneumonia; Hepatic steatosis
M3 HT; Athero-S; Old MI; Parathyroid adenoma
M4 HT; Athero-S; Acute/old MI
M5 NA
M6 NA
M7 HT; Athero-S; Aortic valvular stenosis; Acute MI; Lymphocytic thyroiditis
M8 NA
M9 Athero-S; Small-cell lung carcinoma/liver metastasis; Pulmonary emphysema; Pulmonary embolism
M10 None by history
M11 None by history
M12 HT; Athero-S; Acute/old MI; Pneumonia
M13 NA
M14 NA
M15 Athero-S; Myocardial interstitial fibrosis; Pneumonia; Candida pyelonephritis
M16 NA
M17 NA
M18 Cachexia; Brown cardiac atrophy; Deep vein thrombosis; Pulmonary embolism; Acute/chronic pancreatitis; Pneumonia
M19 Athero-S; Old MI; Bioprosthetic aortic valve; Atypical carcinoid lung tumor/liver metastasis; Pulmonary embolism
M20 Athero-S; Acute renal microinfarct; Pneumonia
M21 NA

Abbreviations: S1–S18 = brains of demented patients with severe cerebral amyloid angiopathy; M1–M21 = brains of demented patients with mild cerebral amyloid angiopathy; HT = history of systemic arterial hypertension; Athero-S = moderate or severe degree of systemic atherosclerosis; NA = not available; MI = myocardial infarction.

CAA severity versus Old microinfarcts

On CD68 immunohistochemistry, old microinfarcts (Figure 1A–C) were present in 14 of 18 SCAA brains, and in 7 of 21 MCAA brains (P = 0.01, two-tailed Fisher’s exact test). The number of old microinfarcts in each block ranged from 0 to 9 in the SCAA group, and from 0 to 2 in the MCAA group. The average number of old microinfarcts across geographic regions in each brain ranged from 0 to 1.95 (mean rank 24.94, sum of ranks 449) in the SCAA group, and from 0 to 0.35 (mean rank 15.76, sum of ranks 331) in the MCAA group (P = 0.008, two-tailed Mann-Whitney U test). Old microinfarcts involved the gray matter in 10 and the white matter in 8 of 18 SCAA brains (Figure 2). Of 21 MCAA brains, old microinfarcts were found in the gray matter in 4 and the white matter in 4 (Figure 2).

Figure 1. Old microinfarcts highlighted on CD68 immunohistochemistry of brains with severe cerebral amyloid angiopathy.

Figure 1

(A) The left frontal cortex of S13 (arrow, ×40 original magnification). (B) The anterior cingulate cortex of S13 (×200 original magnification). (C) The right dorsolateral posterior frontal white matter of S9 (×100 original magnification).

Figure 2.

Figure 2

The average number of old microinfarcts in the gray matter and white matter across brain regions: distribution among 18 brains of demented patients with severe cerebral amyloid angiopathy (S1–S18) and 21 brains of demented patients with mild cerebral amyloid angiopathy (M1–M21).

CAA severity versus Subcortical arteriosclerosis and basal brain atherosclerosis

Subcortical arteriosclerosis was graded as mild, moderate, or severe on the basis of extensiveness of its involvement; in addition, severe arteriosclerosis needed to be accompanied by numerous dilated perivascular spaces (17). Atherosclerosis was also graded as mild, moderate, or severe on the basis of extensiveness of its involvement; additionally, severe atherosclerosis was defined based on the presence of complicated atheromatous plaques exhibiting ulceration, intramural bleeding, thrombosis over the plaque, or calcification (17). By grouping the degree of subcortical arteriosclerosis into “absent or mild” and “moderate or severe,” the latter was observed on H&E staining in 8 of 18 SCAA brains and in 6 of 21 MCAA brains (P = 0.34, two-tailed Fisher’s exact test). Based on the analysis similar to that of subcortical arteriosclerosis, moderate or severe atherosclerosis of the basal brain arteries was present in 10 of 18 SCAA brains and in 11 of 21 MCAA brains (P = 1.0, two-tailed Fisher’s exact test).

CAA severity versus Systemic hypertension, atherosclerosis, and cardiac diseases

Since arterial hypertension, systemic atherosclerosis, and cardiac diseases are known risk factors for stroke in general, these confounding factors were taken into account in our present study and determined according either to the clinical history or general autopsy diagnoses. In this study, cardiac diseases included myocardial infarction of any age, cardiomyopathies, valvular diseases, endocarditis, and arrhythmias. Given that a significant proportion of autopsies in the ADRC cohort were limited to the brain, 14 of 18 SCAA brains and 12 of 21 MCAA brains were accompanied by the information needed in this regard (P = 0.31, two-tailed Fisher’s exact test). A clinical history of hypertension was documented in 5 of 14 SCAA brains and in 4 of 12 MCAA brains (P = 1.0, two-tailed Fisher’s exact test). Moderate or severe systemic atherosclerosis was observed in 6 of 14 SCAA brains and in 9 of 12 MCAA brains (P = 0.13, two-tailed Fisher’s exact test). One or more cardiac diseases were present in 5 of 14 SCAA brains and in 7 of 12 MCAA brains (P = 0.43, two-tailed Fisher’s exact test).

Old microinfarcts versus Subcortical arteriosclerosis and basal brain atherosclerosis

To test whether the presence of old microinfarcts was associated with the degree of subcortical arteriosclerosis and that of basal brain atherosclerosis, we performed statistical analyses similar to those applied to CAA severity. Moderate or severe subcortical arteriosclerosis was observed in 8 of 21 brains with old microinfarcts, and in 6 of 18 brains without old microinfarcts (P = 1.0, two-tailed Fisher’s exact test). Moderate or severe atherosclerosis of the basal brain arteries was present in 11 of 21 brains with old microinfarcts, and in 10 of 18 brains without old microinfarcts (P = 1.0, two-tailed Fisher’s exact test).

Old microinfarcts versus Systemic hypertension, atherosclerosis, and cardiac diseases

A clinical history of hypertension was documented in 5 of 16 patients whose brains had old microinfarcts, and in 4 of 10 of those whose brains lacked old microinfarcts (P = 0.69, two-tailed Fisher’s exact test). Moderate or severe systemic atherosclerosis was observed in 10 of 16 brains with old microinfarcts, and in 5 of 10 brains without old microinfarcts (P = 0.69, two-tailed Fisher’s exact test). One or more cardiac diseases were present in 8 of 16 brains with old microinfarcts, and in 4 of 10 brains without old microinfarcts (P = 0.7, two-tailed Fisher’s exact test).

DISCUSSION

This study compared brains of demented patients with severe CAA to those with mild CAA, and showed that old microinfarcts were present in a significantly higher proportion of brains and in a significantly higher burden in the former group than in the latter. The coexistence of severe CAA and old microinfarcts in brains of demented patients does not necessarily indicate that the former causes the latter; nonetheless, when CAA is severe, its association with microinfarcts is highly significant.

CAA, a type of cerebral microvascular disease, occurs both in sporadic and hereditary forms. In most instances, the amyloid is composed of Aβ peptides 1–40 and 1–42 with an increased Aβ 40/42 ratio in severely affected vessels, compared to that found in senile plaques of AD (2). Sporadic CAA is common in elderly people, both in demented and nondemented groups (12). In a population-based study, severe CAA was present in 21% of 192 elderly brains and was found to be associated significantly with dementia in multivariate analysis controlling for age, brain weight, neuritic and diffuse plaques, neocortical and hippocampal neurofibrillary tangles, Lewy bodies, and cerebrovascular disease (1). In the community-based Honolulu–Asia Aging Study, CAA was present in 44% of 211 brains (28). In 22 clinically diagnosed AD cases in this study, the presence of CAA was strongly associated with worse cognitive impairment even after adjusting for the potential confounders. However, in 16 neuropathologically confirmed AD cases with or without coexistent cerebrovascular disease, the association between CAA and cognitive impairment was not significant after adjusting for the potential confounders. In a CERAD series of 117 AD brains, 83% showed at least a mild degree of CAA, and 26% showed moderate to severe CAA (6). Among 85 AD patients for whom Clinical Dementia Rating scores were obtained within 1 year of death in this CERAD series, no significant correlation was observed between the degree of CAA and severity of dementia.

While some reports in the literature have demonstrated a significant association between CAA and microinfarcts in AD (2325), others have not (6, 19). Evaluation of the severity of CAA varies among laboratories, not only in terms of the staining methods used but also the grading systems employed. Quantitative assessment of the burden of microinfarcts across brain regions may also be important with regard to its effect on cognition. The histologic diagnosis of CAA can be made on Congo red or thioflavin-S staining, or Aβ immunohistochemistry. In grading CAA, one may either qualitatively assess the degree of CAA involvement of individual vessels, or quantitatively determine the proportion of vessels involved in various brain regions, or both (2, 6, 13, 14, 2325, 28, 37). To our knowledge, there are no consensus criteria for grading of CAA severity, though attempts are being made to develop these. In the “Vonsattel system,” the severity of CAA was assessed on Congo red staining by evaluating the degree of involvement of individual vessels. Severe CAA was characterized by extensive amyloid deposition, loss of smooth muscle cells, focal vessel wall fragmentation, and paravascular blood leakage, frequently accompanied by double barreling, microaneurysm formation, and fibrinoid necrosis (so called CAA-associated microangiopathies) (20, 29, 37). Severe CAA based on this qualitative system was found to be associated with spontaneous lobar cerebral hemorrhage.

In other reports the severity of CAA was evaluated qualitatively and quantitatively across 4 brain regions (3 neocortical and 1 hippocampal) on thioflavin-S staining (2325). Severe CAA in AD was shown in these reports to correlate significantly with cerebral hemorrhage and cortical microinfarcts, especially in patients with a history of hypertension. In a CERAD series of 117 AD brains, CAA was graded quantitatively across 5 brain regions (3 neocortical, 1 hippocampal, and 1 entorhinal) by use of amyloid staining methods that varied among the participating laboratories. Hemorrhagic or ischemic cerebral vascular lesions were found in 28% of brains in this CERAD series and were more frequent in brains with moderate to severe CAA. The severity of CAA was shown to be significantly associated with hemorrhage and grossly visible cortical infarcts, but not with subcortical lacunar infarcts or microinfarcts (6). The Honolulu-Asia Aging Study reported that the presence of CAA on Aβ immunohistochemistry and old infarction in AD were independent of each other (19). In this report, neither grading of CAA severity nor semiquantification of old infarction was attempted.

In addition to studies of autopsied brains, a retrospective cross-sectional analysis of brain lesions on multi-sequence magnetic resonance imaging (MRI) among 78 living patients with a diagnosis of probable CAA suggested that clinically silent small subacute infarcts in the cortex and subcortical white matter were associated with advanced CAA accompanied by high hemorrhage burden (18). MRI evidence of chronic infarcts was observed in 18% of these 78 subjects, although their occurrence was not associated with that of small subacute infarcts. A single-case report of focal neurologic episodes, accompanied by MRI evidence of recent ischemia, petechial hemorrhage and focal meningeal enhancement, showed CAA on leptomeningeal biopsy (27). These 2 clinical studies have substantiated a notion of CAA as a risk factor for cerebral ischemia, in addition to intracerebral hemorrhage.

In our present study, CAA was qualitatively graded in accordance with “Vonsattel criteria” (36, 37), and in the severe CAA group the involved vessels frequently exhibited CAA-associated microangiopathies (20, 36), consistent with the most advanced degree of CAA involvement. In addition, old microinfarcts were counted on CD68 immunohistochemistry across various brain regions examined to semiquantitatively determine the burden. We cannot exclude the possibility that some lesions scored as old microinfarcts may represent microhemorrhages within which blood has been cleared or resorbed. Since most of the patients in this study were in advanced ages at death and often affected with a variety of cerebro- and cardiovascular diseases, we cannot exclude the possibility that some microinfarcts found in the brain were caused by cerebral embolism. Nonetheless, these confounding factors existed in both severe CAA and mild CAA groups without statistically significant differences in their frequencies. In addition, we found no statistically significant association between the presence of old microinfarcts and subcortical arteriosclerosis, basal brain atherosclerosis, hypertension, systemic atherosclerosis, cardiac diseases, and patients’ age at death. In case of cerebral embolism, it is more likely to find infarcts of varying sizes, including microscopic, lacunar and large infarcts. Accordingly, in our present study we excluded cases that were recorded to have lacunar or large old infarcts on the autopsy reports. Other limitations of this study were variations in the size of tissue sections (data not shown) and in the number of tissue blocks examined, which were inherent to the retrospective study.

We did not expect to find the large number of microinfarcts in brains involved by CAA even of severe grade, since CAA, in contrast to cerebral embolism, evolves in a chronic slowly-progressive fashion whereby Aβ gradually deposits in the basement membranes of arteriolar walls and eventually replaces vascular smooth muscle cells, leading to progressive luminal narrowing, loss of cerebrovascular autoregulation, and hypoperfusion (8, 11). The gradual development of ischemic process in CAA would allow compensatory mechanisms to operate in the collateral circulation, in contradistinction to the abrupt shower-like nature of vascular occlusion associated with cerebral embolism. In addition, the inherently small size of microinfarcts (≤5 mm in greatest dimension) is subject to sampling errors, as observed in several cases in our present study where microinfarcts were found on H&E-stained slides but no longer present on the corresponding CD68-immunostained slides, and vice versa (data not shown). Although the combined volume of microinfarcts appeared small in each brain examined (data not shown), the presence of microinfarcts indicates the ultimate in the ischemic process. Lesser degrees of vascular insufficiency, together with loss of microvascular autoregulation, can be predicted to exist much more extensively in the brain with severe CAA, which may contribute to cognitive decline, in addition to that caused by the concomitant neurodegenerative diseases.

Our findings suggest that severe CAA in the brains of demented patients is associated with frequent old microinfarcts, which may contribute a vascular component to cognitive impairment. Since the vast majority of CAA cases in our study were associated with AD pathology, it would also be of interest to explore the relationship between the presence of severe CAA and the burden of old microinfarcts in the brains from demented patients with negligible or minimal AD pathology, in a way that has been done in brains from patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (21, 35). Compared to our present study, Haglund et al. (13, 14) have recently shown a significant correlation between severe CAA and cortical microinfarcts in brains from patients with vascular dementia with only minimal AD pathology, suggesting CAA with microinfarcts may represent a subset of “vascular dementia”. Since the apolipoprotein E (ApoE) ε2 allele has been shown to be a risk factor for CAA-associated microangiopathies and intracerebral hemorrhage (22, 40), it is of interest to study the association of ApoE genotyping with the presence of microinfarcts in severe CAA brains.

ACKNOWLEDGMENTS

This work was supported by the NIA grants P50 AG16570 and P01 AG12435, and the Dalijit S. & Elaine Sarkaria Chair in Diagnostic Medicine to H.V.V.

Footnotes

DISCLOSURE

There are no real or potential conflicts of interest for any of the authors to disclose.

REFERENCES

  • 1.Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Lancet. 2001;357(9251):169–175. doi: 10.1016/s0140-6736(00)03589-3. [DOI] [PubMed] [Google Scholar]
  • 2.Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol. 1998;57:353–359. doi: 10.1097/00005072-199804000-00008. [DOI] [PubMed] [Google Scholar]
  • 3.Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259. doi: 10.1007/BF00308809. [DOI] [PubMed] [Google Scholar]
  • 4.Cadavid D, Mena H, Koeller K, Frommelt RA. Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol. 2000;59:768–773. doi: 10.1093/jnen/59.9.768. [DOI] [PubMed] [Google Scholar]
  • 5.Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol. 2006;60:677–687. doi: 10.1002/ana.21009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 1996;46:1592–1596. doi: 10.1212/wnl.46.6.1592. [DOI] [PubMed] [Google Scholar]
  • 7.Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry. 1997;63:749–753. doi: 10.1136/jnnp.63.6.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 2001;64:575–611. doi: 10.1016/s0301-0082(00)00068-x. [DOI] [PubMed] [Google Scholar]
  • 9.Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004;128:32–38. doi: 10.5858/2004-128-32-CID. [DOI] [PubMed] [Google Scholar]
  • 10.Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology. 1995;45:461–466. doi: 10.1212/wnl.45.3.461. [DOI] [PubMed] [Google Scholar]
  • 11.Greenberg SM. Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis. 2002;13 Suppl 2:42–47. doi: 10.1159/000049149. [DOI] [PubMed] [Google Scholar]
  • 12.Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35 Suppl 1:2616–2619. doi: 10.1161/01.STR.0000143224.36527.44. [DOI] [PubMed] [Google Scholar]
  • 13.Haglund M, Passant U, Sjöbeck M, Ghebremedhin E, Englund E. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry. 2006;21:681–687. doi: 10.1002/gps.1550. [DOI] [PubMed] [Google Scholar]
  • 14.Haglund M, Sjöbeck M, Englund E. Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord. 2004;18:132–137. doi: 10.1159/000079192. [DOI] [PubMed] [Google Scholar]
  • 15.Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1998;51:159–162. doi: 10.1212/wnl.51.1.159. [DOI] [PubMed] [Google Scholar]
  • 16.Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci. 2004;226:75–80. doi: 10.1016/j.jns.2004.09.019. [DOI] [PubMed] [Google Scholar]
  • 17.Kalimo H, Kaste M, Haltia M. Vascular diseases. In: Graham DI, Lantos PL, editors. Greenfield's neuropathology. vol. 1. London: Arnold; 2002. pp. 288–330. [Google Scholar]
  • 18.Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg SM. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology. 2009;72:1230–1235. doi: 10.1212/01.wnl.0000345666.83318.03. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: Vascular origins? Results from the HAAS autopsy study. Neurobiol Aging. 2007;29:1587–1590. doi: 10.1016/j.neurobiolaging.2007.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol. 1986;45:79–90. [PubMed] [Google Scholar]
  • 21.Natté R, Vinters HV, Maat-Schieman MLC, Bornebroek M, Haan J, Roos RAC, van Duinen SG. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke. 1998;29:1588–1594. doi: 10.1161/01.str.29.8.1588. [DOI] [PubMed] [Google Scholar]
  • 22.Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41:716–721. doi: 10.1002/ana.410410607. [DOI] [PubMed] [Google Scholar]
  • 23.Olichney JM, Ellis RJ, Katzman R, Sabbagh MN, Hansen L. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer's disease. Ann N Y Acad Sci. 1997;826:493–497. doi: 10.1111/j.1749-6632.1997.tb48511.x. [DOI] [PubMed] [Google Scholar]
  • 24.Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol. 1995;52:702–708. doi: 10.1001/archneur.1995.00540310076019. [DOI] [PubMed] [Google Scholar]
  • 25.Olichney JM, Hansen LA, Hofstetter CR, Lee JH, Katzman R, Thal LJ. Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol. 2000;57:869–874. doi: 10.1001/archneur.57.6.869. [DOI] [PubMed] [Google Scholar]
  • 26.Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, Nelson J, Hardman J, Masaki K, Vogt MR, Launer L, White LR. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol. 2005;57:98–103. doi: 10.1002/ana.20318. [DOI] [PubMed] [Google Scholar]
  • 27.Peysson S, Nighoghossian N, Derex L, Jouvet A, Hermier M, Trouillas P. Cerebral amyloid angiopathy revealed by transient ischemic events: contribution of MRI to diagnosis and pathophysiology study. Rev Neurol (Paris) 2003;159:203–205. (abstract) [PubMed] [Google Scholar]
  • 28.Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58:1629–1634. doi: 10.1212/wnl.58.11.1629. [DOI] [PubMed] [Google Scholar]
  • 29.Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol. 2003;62:885–898. doi: 10.1093/jnen/62.9.885. [DOI] [PubMed] [Google Scholar]
  • 30.Selnes OA, Vinters HV. Vascular cognitive impairment. Nat Clin Pract Neurol. 2006;2:538–547. doi: 10.1038/ncpneuro0294. [DOI] [PubMed] [Google Scholar]
  • 31.Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813–817. [PubMed] [Google Scholar]
  • 32.Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406–413. doi: 10.1002/ana.21208. [DOI] [PubMed] [Google Scholar]
  • 33.Vinters HV. Imaging cerebral microvascular amyloid. Ann Neurol. 2007;62:209–212. doi: 10.1002/ana.21215. [DOI] [PubMed] [Google Scholar]
  • 34.Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 2000;59:931–945. doi: 10.1093/jnen/59.11.931. [DOI] [PubMed] [Google Scholar]
  • 35.Vinters HV, Natté R, Maat-Schieman MLC, van Duinen SG, Hegeman-Kleinn I, Welling-Graafland C, Haan J, Roos RAC. Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D) Acta Neuropathol. 1998;95:235–244. doi: 10.1007/s004010050793. [DOI] [PubMed] [Google Scholar]
  • 36.Vinters HV, Vonsattel J. Neuropathologic features and grading of Alzheimer’s related and sporadic CAA. In: Verbeek MM, de Waal RMW, Vinters HV, editors. Cerebral amyloid angiopathy in Alzheimer’s disease and related disorders. Dordrecht: Kluver Academic Publishers; 2000. pp. 137–155. [Google Scholar]
  • 37.Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP., Jr Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637–649. doi: 10.1002/ana.410300503. [DOI] [PubMed] [Google Scholar]
  • 38.White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci. 2002;977:9–23. doi: 10.1111/j.1749-6632.2002.tb04794.x. [DOI] [PubMed] [Google Scholar]
  • 39.Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, Mukaetova-Ladinska E, McGee MA, O'Sullivan A, O'Connor D, Paykel ES, Huppert FA. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci. 2000;903:490–496. doi: 10.1111/j.1749-6632.2000.tb06404.x. [DOI] [PubMed] [Google Scholar]
  • 40.Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006;16:30–39. doi: 10.1111/j.1750-3639.2006.tb00559.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES